Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study

Launched by BEIJING FRIENDSHIP HOSPITAL · Aug 10, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how a medication called sacubitril/valsartan affects heart function in patients with high blood pressure (hypertension) who also have different body weights (measured by Body Mass Index or BMI). The researchers want to understand how this medication works in real-world settings, particularly using a method called cardiac magnetic resonance imaging (CMR) to assess heart health.

To participate in the trial, you need to be between 18 and 70 years old and have essential hypertension (which means high blood pressure that isn't caused by another health issue). However, you won't be eligible if you have certain conditions like severe heart problems within the last six months or other serious diseases. If you join the study, you can expect to undergo tests to monitor your heart's function while taking the medication. The trial is currently looking for participants, and it aims to gather important information to help improve treatments for people with high blood pressure.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with essential hypertension
• • 18-70 years old
• • No major barriers to provide written consent
• Exclusion Criteria:
• • Secondary hypertension, except because of sleep apnea
• • cardiovascular disease (myocardial infarction, heart failure, stroke or coronary revascularization) within 6 months
• • Severe concomitant diseases (autoimmune disease, malignancy, late stage of liver diseases, respiratory diseases and digestive diseases)
• • Unable to understand or comply with the study procedures